From the Editor

Jun 01, 2012
Pharmaceutical Executive
As the old Broadway song goes, June is busting out all over—and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.
May 01, 2012
Pharmaceutical Executive
The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.
Apr 01, 2012
Pharmaceutical Executive
Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Mar 01, 2012
Pharmaceutical Executive
Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.
Feb 01, 2012
Pharmaceutical Executive
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
Dec 01, 2011
Pharmaceutical Executive
The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.
Nov 01, 2011
Pharmaceutical Executive
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.
Oct 01, 2011
Pharmaceutical Executive
Pharm Exec celebrates its 30th birthday with a gathering of 30 of the industry's key influencers of the last three decades.
Sep 01, 2011
Pharmaceutical Executive
Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
Aug 01, 2011
Pharmaceutical Executive
What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
native1_300x100
lorem ipsum